Organigram Global and Sanity Group jointly announced the official closing of Organigram’s acquisition of the Germany-based cannabis company that was originally announced in February. Combining cash and shares as part of its international expansion strategy, the deal is valued at €107.3 million. The transaction was supported by €40.3 million in new financing from British American Tobacco and additional credit facilities, highlighting BAT’s continued backing of Organigram’s growth initiatives. The deal marks the final deployment of funds from the Jupiter strategic investment pool and strengthens Organigram’s position in the European cannabis market.
Tag: acquisition
-
BAT Ups Investment in Organigram
Credit: Roxxy Photos Organigram Holdings Inc. has extended its relationship with British American Tobacco. The move boosts the Canadian cannabis producer’s financial strength and positioning it to expand globally.
Organigram said in a statement that BAT is investing a further $90.5 million in the business, building on an initial $160 million injection back in 2021.
Organigram said the investment will allow it to extend its footprint beyond Canada, and also strengthen its financial position for long-term, sustainable growth, according to media reports.
“This investment bolsters an already strong balance sheet and solidifies our position as a leading cannabis company,” said Beena Goldenberg, chief executive of Organigram.
The firm said the deal enables it to invest in growing the topline of its core business, while optimizing operations to deliver on cost-saving efficiencies, thus accelerating earnings growth.
Organigram will use the majority of the investment to create a strategic investment pool, named Jupiter.
Jupiter will target investments in emerging cannabis opportunities that will enable Organigram to apply its industry-leading capabilities to new markets, it said.